カテゴリー： Market Monitor Global, 世界, 医療/バイオ

喘息＆COPD治療薬の世界市場見通し2023年-2029年

◆英語タイトル：Drugs for Asthma and COPD Market, Global Outlook and Forecast 2023-2029
	◆商品コード：MMG23LY8487 ◆発行会社（リサーチ会社）：Market Monitor Global ◆発行日：2023年7月（※2025年版があります。お問い合わせください。） ◆ページ数：114 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後2-3営業日） ◆調査対象地域：グローバル ◆産業分野：医薬品＆ヘルスケア

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥468,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥608,400	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥702,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Drugs for Asthma and COPD Market 調査レポートは次の情報を含め、グローバルにおけるの喘息＆COPD治療薬市場規模と予測を収録しています。・世界の喘息＆COPD治療薬市場：売上、2018年-2023年、2024年-2029年
・世界の喘息＆COPD治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の喘息＆COPD治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「ジェネリック治療薬」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

喘息＆COPD治療薬のグローバル主要企業は、GSK、 Novartis、 Merck、 Abbott、 Boehringer Ingelheim、 AstraZeneca、 Roche、 Teva、 Vectura、 Pfizer、 Mylan、 Allergan、 Cipla、 Akorn、 Apotexなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、喘息＆COPD治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の喘息＆COPD治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の喘息＆COPD治療薬市場：タイプ別市場シェア、2022年
・ジェネリック治療薬、特許治療薬

世界の喘息＆COPD治療薬市場：用途別、2018年-2023年、2024年-2029年
世界の喘息＆COPD治療薬市場：用途別市場シェア、2022年
・喘息、COPD

世界の喘息＆COPD治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の喘息＆COPD治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における喘息＆COPD治療薬のグローバル売上、2018年-2023年
・主要企業における喘息＆COPD治療薬のグローバル売上シェア、2022年
・主要企業における喘息＆COPD治療薬のグローバル販売量、2018年-2023年
・主要企業における喘息＆COPD治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
GSK、 Novartis、 Merck、 Abbott、 Boehringer Ingelheim、 AstraZeneca、 Roche、 Teva、 Vectura、 Pfizer、 Mylan、 Allergan、 Cipla、 Akorn、 Apotex

*************************************************************

・調査・分析レポートの概要
喘息＆COPD治療薬市場の定義
市場セグメント
世界の喘息＆COPD治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の喘息＆COPD治療薬市場規模
世界の喘息＆COPD治療薬市場規模：2022年 VS 2029年
世界の喘息＆COPD治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの喘息＆COPD治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の喘息＆COPD治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：ジェネリック治療薬、特許治療薬
喘息＆COPD治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：喘息、COPD
喘息＆COPD治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別喘息＆COPD治療薬市場規模 2022年と2029年
地域別喘息＆COPD治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
GSK、 Novartis、 Merck、 Abbott、 Boehringer Ingelheim、 AstraZeneca、 Roche、 Teva、 Vectura、 Pfizer、 Mylan、 Allergan、 Cipla、 Akorn、 Apotex
...

Drugs used as treatments for asthma and COPD
This report aims to provide a comprehensive presentation of the global market for Drugs for Asthma and COPD, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Asthma and COPD. This report contains market size and forecasts of Drugs for Asthma and COPD in global, including the following market information:
Global Drugs for Asthma and COPD Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Drugs for Asthma and COPD Market Sales, 2018-2023, 2024-2029, (MT)
Global top five Drugs for Asthma and COPD companies in 2022 (%)
The global Drugs for Asthma and COPD market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Generic Drugs Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Drugs for Asthma and COPD include GSK, Novartis, Merck, Abbott, Boehringer Ingelheim, AstraZeneca, Roche, Teva and Vectura, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Drugs for Asthma and COPD manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Drugs for Asthma and COPD Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (MT)
Global Drugs for Asthma and COPD Market Segment Percentages, by Type, 2022 (%)
Generic Drugs
Patented Drugs
Global Drugs for Asthma and COPD Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (MT)
Global Drugs for Asthma and COPD Market Segment Percentages, by Application, 2022 (%)
Asthma
COPD
Global Drugs for Asthma and COPD Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (MT)
Global Drugs for Asthma and COPD Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Drugs for Asthma and COPD revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Drugs for Asthma and COPD revenues share in global market, 2022 (%)
Key companies Drugs for Asthma and COPD sales in global market, 2018-2023 (Estimated), (MT)
Key companies Drugs for Asthma and COPD sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
GSK
Novartis
Merck
Abbott
Boehringer Ingelheim
AstraZeneca
Roche
Teva
Vectura
Pfizer
Mylan
Allergan
Cipla
Akorn
Apotex
Outline of Major Chapters:
Chapter 1: Introduces the definition of Drugs for Asthma and COPD, market overview.
Chapter 2: Global Drugs for Asthma and COPD market size in revenue and volume.
Chapter 3: Detailed analysis of Drugs for Asthma and COPD manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Drugs for Asthma and COPD in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Drugs for Asthma and COPD capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Drugs for Asthma and COPD Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Drugs for Asthma and COPD Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Drugs for Asthma and COPD Overall Market Size
2.1 Global Drugs for Asthma and COPD Market Size: 2022 VS 2029
2.2 Global Drugs for Asthma and COPD Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Drugs for Asthma and COPD Sales: 2018-2029
3 Company Landscape
3.1 Top Drugs for Asthma and COPD Players in Global Market
3.2 Top Global Drugs for Asthma and COPD Companies Ranked by Revenue
3.3 Global Drugs for Asthma and COPD Revenue by Companies
3.4 Global Drugs for Asthma and COPD Sales by Companies
3.5 Global Drugs for Asthma and COPD Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Drugs for Asthma and COPD Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Drugs for Asthma and COPD Product Type
3.8 Tier 1, Tier 2 and Tier 3 Drugs for Asthma and COPD Players in Global Market
3.8.1 List of Global Tier 1 Drugs for Asthma and COPD Companies
3.8.2 List of Global Tier 2 and Tier 3 Drugs for Asthma and COPD Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Drugs for Asthma and COPD Market Size Markets, 2022 & 2029
4.1.2 Generic Drugs
4.1.3 Patented Drugs
4.2 By Type – Global Drugs for Asthma and COPD Revenue & Forecasts
4.2.1 By Type – Global Drugs for Asthma and COPD Revenue, 2018-2023
4.2.2 By Type – Global Drugs for Asthma and COPD Revenue, 2024-2029
4.2.3 By Type – Global Drugs for Asthma and COPD Revenue Market Share, 2018-2029
4.3 By Type – Global Drugs for Asthma and COPD Sales & Forecasts
4.3.1 By Type – Global Drugs for Asthma and COPD Sales, 2018-2023
4.3.2 By Type – Global Drugs for Asthma and COPD Sales, 2024-2029
4.3.3 By Type – Global Drugs for Asthma and COPD Sales Market Share, 2018-2029
4.4 By Type – Global Drugs for Asthma and COPD Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Drugs for Asthma and COPD Market Size, 2022 & 2029
5.1.2 Asthma
5.1.3 COPD
5.2 By Application – Global Drugs for Asthma and COPD Revenue & Forecasts
5.2.1 By Application – Global Drugs for Asthma and COPD Revenue, 2018-2023
5.2.2 By Application – Global Drugs for Asthma and COPD Revenue, 2024-2029
5.2.3 By Application – Global Drugs for Asthma and COPD Revenue Market Share, 2018-2029
5.3 By Application – Global Drugs for Asthma and COPD Sales & Forecasts
5.3.1 By Application – Global Drugs for Asthma and COPD Sales, 2018-2023
5.3.2 By Application – Global Drugs for Asthma and COPD Sales, 2024-2029
5.3.3 By Application – Global Drugs for Asthma and COPD Sales Market Share, 2018-2029
5.4 By Application – Global Drugs for Asthma and COPD Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Drugs for Asthma and COPD Market Size, 2022 & 2029
6.2 By Region – Global Drugs for Asthma and COPD Revenue & Forecasts
6.2.1 By Region – Global Drugs for Asthma and COPD Revenue, 2018-2023
6.2.2 By Region – Global Drugs for Asthma and COPD Revenue, 2024-2029
6.2.3 By Region – Global Drugs for Asthma and COPD Revenue Market Share, 2018-2029
6.3 By Region – Global Drugs for Asthma and COPD Sales & Forecasts
6.3.1 By Region – Global Drugs for Asthma and COPD Sales, 2018-2023
6.3.2 By Region – Global Drugs for Asthma and COPD Sales, 2024-2029
6.3.3 By Region – Global Drugs for Asthma and COPD Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Drugs for Asthma and COPD Revenue, 2018-2029
6.4.2 By Country – North America Drugs for Asthma and COPD Sales, 2018-2029
6.4.3 US Drugs for Asthma and COPD Market Size, 2018-2029
6.4.4 Canada Drugs for Asthma and COPD Market Size, 2018-2029
6.4.5 Mexico Drugs for Asthma and COPD Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Drugs for Asthma and COPD Revenue, 2018-2029
6.5.2 By Country – Europe Drugs for Asthma and COPD Sales, 2018-2029
6.5.3 Germany Drugs for Asthma and COPD Market Size, 2018-2029
6.5.4 France Drugs for Asthma and COPD Market Size, 2018-2029
6.5.5 U.K. Drugs for Asthma and COPD Market Size, 2018-2029
6.5.6 Italy Drugs for Asthma and COPD Market Size, 2018-2029
6.5.7 Russia Drugs for Asthma and COPD Market Size, 2018-2029
6.5.8 Nordic Countries Drugs for Asthma and COPD Market Size, 2018-2029
6.5.9 Benelux Drugs for Asthma and COPD Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Drugs for Asthma and COPD Revenue, 2018-2029
6.6.2 By Region – Asia Drugs for Asthma and COPD Sales, 2018-2029
6.6.3 China Drugs for Asthma and COPD Market Size, 2018-2029
6.6.4 Japan Drugs for Asthma and COPD Market Size, 2018-2029
6.6.5 South Korea Drugs for Asthma and COPD Market Size, 2018-2029
6.6.6 Southeast Asia Drugs for Asthma and COPD Market Size, 2018-2029
6.6.7 India Drugs for Asthma and COPD Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Drugs for Asthma and COPD Revenue, 2018-2029
6.7.2 By Country – South America Drugs for Asthma and COPD Sales, 2018-2029
6.7.3 Brazil Drugs for Asthma and COPD Market Size, 2018-2029
6.7.4 Argentina Drugs for Asthma and COPD Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Drugs for Asthma and COPD Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Drugs for Asthma and COPD Sales, 2018-2029
6.8.3 Turkey Drugs for Asthma and COPD Market Size, 2018-2029
6.8.4 Israel Drugs for Asthma and COPD Market Size, 2018-2029
6.8.5 Saudi Arabia Drugs for Asthma and COPD Market Size, 2018-2029
6.8.6 UAE Drugs for Asthma and COPD Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 GSK
7.1.1 GSK Company Summary
7.1.2 GSK Business Overview
7.1.3 GSK Drugs for Asthma and COPD Major Product Offerings
7.1.4 GSK Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.1.5 GSK Key News & Latest Developments
7.2 Novartis
7.2.1 Novartis Company Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Drugs for Asthma and COPD Major Product Offerings
7.2.4 Novartis Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.2.5 Novartis Key News & Latest Developments
7.3 Merck
7.3.1 Merck Company Summary
7.3.2 Merck Business Overview
7.3.3 Merck Drugs for Asthma and COPD Major Product Offerings
7.3.4 Merck Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.3.5 Merck Key News & Latest Developments
7.4 Abbott
7.4.1 Abbott Company Summary
7.4.2 Abbott Business Overview
7.4.3 Abbott Drugs for Asthma and COPD Major Product Offerings
7.4.4 Abbott Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.4.5 Abbott Key News & Latest Developments
7.5 Boehringer Ingelheim
7.5.1 Boehringer Ingelheim Company Summary
7.5.2 Boehringer Ingelheim Business Overview
7.5.3 Boehringer Ingelheim Drugs for Asthma and COPD Major Product Offerings
7.5.4 Boehringer Ingelheim Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.5.5 Boehringer Ingelheim Key News & Latest Developments
7.6 AstraZeneca
7.6.1 AstraZeneca Company Summary
7.6.2 AstraZeneca Business Overview
7.6.3 AstraZeneca Drugs for Asthma and COPD Major Product Offerings
7.6.4 AstraZeneca Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.6.5 AstraZeneca Key News & Latest Developments
7.7 Roche
7.7.1 Roche Company Summary
7.7.2 Roche Business Overview
7.7.3 Roche Drugs for Asthma and COPD Major Product Offerings
7.7.4 Roche Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.7.5 Roche Key News & Latest Developments
7.8 Teva
7.8.1 Teva Company Summary
7.8.2 Teva Business Overview
7.8.3 Teva Drugs for Asthma and COPD Major Product Offerings
7.8.4 Teva Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.8.5 Teva Key News & Latest Developments
7.9 Vectura
7.9.1 Vectura Company Summary
7.9.2 Vectura Business Overview
7.9.3 Vectura Drugs for Asthma and COPD Major Product Offerings
7.9.4 Vectura Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.9.5 Vectura Key News & Latest Developments
7.10 Pfizer
7.10.1 Pfizer Company Summary
7.10.2 Pfizer Business Overview
7.10.3 Pfizer Drugs for Asthma and COPD Major Product Offerings
7.10.4 Pfizer Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.10.5 Pfizer Key News & Latest Developments
7.11 Mylan
7.11.1 Mylan Company Summary
7.11.2 Mylan Drugs for Asthma and COPD Business Overview
7.11.3 Mylan Drugs for Asthma and COPD Major Product Offerings
7.11.4 Mylan Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.11.5 Mylan Key News & Latest Developments
7.12 Allergan
7.12.1 Allergan Company Summary
7.12.2 Allergan Drugs for Asthma and COPD Business Overview
7.12.3 Allergan Drugs for Asthma and COPD Major Product Offerings
7.12.4 Allergan Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.12.5 Allergan Key News & Latest Developments
7.13 Cipla
7.13.1 Cipla Company Summary
7.13.2 Cipla Drugs for Asthma and COPD Business Overview
7.13.3 Cipla Drugs for Asthma and COPD Major Product Offerings
7.13.4 Cipla Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.13.5 Cipla Key News & Latest Developments
7.14 Akorn
7.14.1 Akorn Company Summary
7.14.2 Akorn Business Overview
7.14.3 Akorn Drugs for Asthma and COPD Major Product Offerings
7.14.4 Akorn Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.14.5 Akorn Key News & Latest Developments
7.15 Apotex
7.15.1 Apotex Company Summary
7.15.2 Apotex Business Overview
7.15.3 Apotex Drugs for Asthma and COPD Major Product Offerings
7.15.4 Apotex Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.15.5 Apotex Key News & Latest Developments
8 Global Drugs for Asthma and COPD Production Capacity, Analysis
8.1 Global Drugs for Asthma and COPD Production Capacity, 2018-2029
8.2 Drugs for Asthma and COPD Production Capacity of Key Manufacturers in Global Market
8.3 Global Drugs for Asthma and COPD Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Drugs for Asthma and COPD Supply Chain Analysis
10.1 Drugs for Asthma and COPD Industry Value Chain
10.2 Drugs for Asthma and COPD Upstream Market
10.3 Drugs for Asthma and COPD Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Drugs for Asthma and COPD Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Drugs for Asthma and COPD in Global Market
Table 2. Top Drugs for Asthma and COPD Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Drugs for Asthma and COPD Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Drugs for Asthma and COPD Revenue Share by Companies, 2018-2023
Table 5. Global Drugs for Asthma and COPD Sales by Companies, (MT), 2018-2023
Table 6. Global Drugs for Asthma and COPD Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Drugs for Asthma and COPD Price (2018-2023) & (USD/Kg)
Table 8. Global Manufacturers Drugs for Asthma and COPD Product Type
Table 9. List of Global Tier 1 Drugs for Asthma and COPD Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Drugs for Asthma and COPD Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Drugs for Asthma and COPD Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Drugs for Asthma and COPD Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Drugs for Asthma and COPD Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Drugs for Asthma and COPD Sales (MT), 2018-2023
Table 15. By Type - Global Drugs for Asthma and COPD Sales (MT), 2024-2029
Table 16. By Application – Global Drugs for Asthma and COPD Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Drugs for Asthma and COPD Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Drugs for Asthma and COPD Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Drugs for Asthma and COPD Sales (MT), 2018-2023
Table 20. By Application - Global Drugs for Asthma and COPD Sales (MT), 2024-2029
Table 21. By Region – Global Drugs for Asthma and COPD Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Drugs for Asthma and COPD Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Drugs for Asthma and COPD Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Drugs for Asthma and COPD Sales (MT), 2018-2023
Table 25. By Region - Global Drugs for Asthma and COPD Sales (MT), 2024-2029
Table 26. By Country - North America Drugs for Asthma and COPD Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Drugs for Asthma and COPD Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Drugs for Asthma and COPD Sales, (MT), 2018-2023
Table 29. By Country - North America Drugs for Asthma and COPD Sales, (MT), 2024-2029
Table 30. By Country - Europe Drugs for Asthma and COPD Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Drugs for Asthma and COPD Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Drugs for Asthma and COPD Sales, (MT), 2018-2023
Table 33. By Country - Europe Drugs for Asthma and COPD Sales, (MT), 2024-2029
Table 34. By Region - Asia Drugs for Asthma and COPD Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Drugs for Asthma and COPD Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Drugs for Asthma and COPD Sales, (MT), 2018-2023
Table 37. By Region - Asia Drugs for Asthma and COPD Sales, (MT), 2024-2029
Table 38. By Country - South America Drugs for Asthma and COPD Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Drugs for Asthma and COPD Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Drugs for Asthma and COPD Sales, (MT), 2018-2023
Table 41. By Country - South America Drugs for Asthma and COPD Sales, (MT), 2024-2029
Table 42. By Country - Middle East & Africa Drugs for Asthma and COPD Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Drugs for Asthma and COPD Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Drugs for Asthma and COPD Sales, (MT), 2018-2023
Table 45. By Country - Middle East & Africa Drugs for Asthma and COPD Sales, (MT), 2024-2029
Table 46. GSK Company Summary
Table 47. GSK Drugs for Asthma and COPD Product Offerings
Table 48. GSK Drugs for Asthma and COPD Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2018-2023)
Table 49. GSK Key News & Latest Developments
Table 50. Novartis Company Summary
Table 51. Novartis Drugs for Asthma and COPD Product Offerings
Table 52. Novartis Drugs for Asthma and COPD Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2018-2023)
Table 53. Novartis Key News & Latest Developments
Table 54. Merck Company Summary
Table 55. Merck Drugs for Asthma and COPD Product Offerings
Table 56. Merck Drugs for Asthma and COPD Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2018-2023)
Table 57. Merck Key News & Latest Developments
Table 58. Abbott Company Summary
Table 59. Abbott Drugs for Asthma and COPD Product Offerings
Table 60. Abbott Drugs for Asthma and COPD Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2018-2023)
Table 61. Abbott Key News & Latest Developments
Table 62. Boehringer Ingelheim Company Summary
Table 63. Boehringer Ingelheim Drugs for Asthma and COPD Product Offerings
Table 64. Boehringer Ingelheim Drugs for Asthma and COPD Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2018-2023)
Table 65. Boehringer Ingelheim Key News & Latest Developments
Table 66. AstraZeneca Company Summary
Table 67. AstraZeneca Drugs for Asthma and COPD Product Offerings
Table 68. AstraZeneca Drugs for Asthma and COPD Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2018-2023)
Table 69. AstraZeneca Key News & Latest Developments
Table 70. Roche Company Summary
Table 71. Roche Drugs for Asthma and COPD Product Offerings
Table 72. Roche Drugs for Asthma and COPD Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2018-2023)
Table 73. Roche Key News & Latest Developments
Table 74. Teva Company Summary
Table 75. Teva Drugs for Asthma and COPD Product Offerings
Table 76. Teva Drugs for Asthma and COPD Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2018-2023)
Table 77. Teva Key News & Latest Developments
Table 78. Vectura Company Summary
Table 79. Vectura Drugs for Asthma and COPD Product Offerings
Table 80. Vectura Drugs for Asthma and COPD Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2018-2023)
Table 81. Vectura Key News & Latest Developments
Table 82. Pfizer Company Summary
Table 83. Pfizer Drugs for Asthma and COPD Product Offerings
Table 84. Pfizer Drugs for Asthma and COPD Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2018-2023)
Table 85. Pfizer Key News & Latest Developments
Table 86. Mylan Company Summary
Table 87. Mylan Drugs for Asthma and COPD Product Offerings
Table 88. Mylan Drugs for Asthma and COPD Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2018-2023)
Table 89. Mylan Key News & Latest Developments
Table 90. Allergan Company Summary
Table 91. Allergan Drugs for Asthma and COPD Product Offerings
Table 92. Allergan Drugs for Asthma and COPD Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2018-2023)
Table 93. Allergan Key News & Latest Developments
Table 94. Cipla Company Summary
Table 95. Cipla Drugs for Asthma and COPD Product Offerings
Table 96. Cipla Drugs for Asthma and COPD Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2018-2023)
Table 97. Cipla Key News & Latest Developments
Table 98. Akorn Company Summary
Table 99. Akorn Drugs for Asthma and COPD Product Offerings
Table 100. Akorn Drugs for Asthma and COPD Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2018-2023)
Table 101. Akorn Key News & Latest Developments
Table 102. Apotex Company Summary
Table 103. Apotex Drugs for Asthma and COPD Product Offerings
Table 104. Apotex Drugs for Asthma and COPD Sales (MT), Revenue (US$, Mn) and Average Price (USD/Kg) (2018-2023)
Table 105. Apotex Key News & Latest Developments
Table 106. Drugs for Asthma and COPD Production Capacity (MT) of Key Manufacturers in Global Market, 2021-2023 (MT)
Table 107. Global Drugs for Asthma and COPD Capacity Market Share of Key Manufacturers, 2021-2023
Table 108. Global Drugs for Asthma and COPD Production by Region, 2018-2023 (MT)
Table 109. Global Drugs for Asthma and COPD Production by Region, 2024-2029 (MT)
Table 110. Drugs for Asthma and COPD Market Opportunities & Trends in Global Market
Table 111. Drugs for Asthma and COPD Market Drivers in Global Market
Table 112. Drugs for Asthma and COPD Market Restraints in Global Market
Table 113. Drugs for Asthma and COPD Raw Materials
Table 114. Drugs for Asthma and COPD Raw Materials Suppliers in Global Market
Table 115. Typical Drugs for Asthma and COPD Downstream
Table 116. Drugs for Asthma and COPD Downstream Clients in Global Market
Table 117. Drugs for Asthma and COPD Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Drugs for Asthma and COPD Segment by Type in 2022
Figure 2. Drugs for Asthma and COPD Segment by Application in 2022
Figure 3. Global Drugs for Asthma and COPD Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Drugs for Asthma and COPD Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Drugs for Asthma and COPD Revenue, 2018-2029 (US$, Mn)
Figure 7. Drugs for Asthma and COPD Sales in Global Market: 2018-2029 (MT)
Figure 8. The Top 3 and 5 Players Market Share by Drugs for Asthma and COPD Revenue in 2022
Figure 9. By Type - Global Drugs for Asthma and COPD Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Drugs for Asthma and COPD Revenue Market Share, 2018-2029
Figure 11. By Type - Global Drugs for Asthma and COPD Sales Market Share, 2018-2029
Figure 12. By Type - Global Drugs for Asthma and COPD Price (USD/Kg), 2018-2029
Figure 13. By Application - Global Drugs for Asthma and COPD Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Drugs for Asthma and COPD Revenue Market Share, 2018-2029
Figure 15. By Application - Global Drugs for Asthma and COPD Sales Market Share, 2018-2029
Figure 16. By Application - Global Drugs for Asthma and COPD Price (USD/Kg), 2018-2029
Figure 17. By Region - Global Drugs for Asthma and COPD Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Drugs for Asthma and COPD Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Drugs for Asthma and COPD Revenue Market Share, 2018-2029
Figure 20. By Region - Global Drugs for Asthma and COPD Sales Market Share, 2018-2029
Figure 21. By Country - North America Drugs for Asthma and COPD Revenue Market Share, 2018-2029
Figure 22. By Country - North America Drugs for Asthma and COPD Sales Market Share, 2018-2029
Figure 23. US Drugs for Asthma and COPD Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Drugs for Asthma and COPD Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Drugs for Asthma and COPD Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Drugs for Asthma and COPD Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Drugs for Asthma and COPD Sales Market Share, 2018-2029
Figure 28. Germany Drugs for Asthma and COPD Revenue, (US$, Mn), 2018-2029
Figure 29. France Drugs for Asthma and COPD Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Drugs for Asthma and COPD Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Drugs for Asthma and COPD Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Drugs for Asthma and COPD Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Drugs for Asthma and COPD Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Drugs for Asthma and COPD Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Drugs for Asthma and COPD Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Drugs for Asthma and COPD Sales Market Share, 2018-2029
Figure 37. China Drugs for Asthma and COPD Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Drugs for Asthma and COPD Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Drugs for Asthma and COPD Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Drugs for Asthma and COPD Revenue, (US$, Mn), 2018-2029
Figure 41. India Drugs for Asthma and COPD Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Drugs for Asthma and COPD Revenue Market Share, 2018-2029
Figure 43. By Country - South America Drugs for Asthma and COPD Sales Market Share, 2018-2029
Figure 44. Brazil Drugs for Asthma and COPD Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Drugs for Asthma and COPD Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Drugs for Asthma and COPD Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Drugs for Asthma and COPD Sales Market Share, 2018-2029
Figure 48. Turkey Drugs for Asthma and COPD Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Drugs for Asthma and COPD Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Drugs for Asthma and COPD Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Drugs for Asthma and COPD Revenue, (US$, Mn), 2018-2029
Figure 52. Global Drugs for Asthma and COPD Production Capacity (MT), 2018-2029
Figure 53. The Percentage of Production Drugs for Asthma and COPD by Region, 2022 VS 2029
Figure 54. Drugs for Asthma and COPD Industry Value Chain
Figure 55. Marketing Channels

※参考情報

喘息と慢性閉塞性肺疾患（COPD）は、呼吸器系の疾患であり、治療にはさまざまな薬剤が用いられています。これらの疾患は、日本を含む世界中で多くの人々に影響を与えており、患者の生活の質や日常生活に大きな影響を及ぼすことがあります。喘息は気道の炎症と過敏性によって特徴づけられ、COPDは主に長期的な喫煙や環境因子に起因する気道の慢性的な炎症と閉塞を伴います。

喘息とCOPDの治療薬は、基本的には疾患の症状を緩和し、発作の予防を目的としています。これらの治療薬は、気道の炎症を抑えたり、気道を広げたりする働きがあります。治療薬は主に吸入薬として提供されることが多く、直接気道に作用するため、効率的に成分を届けることができます。

喘息の治療薬には主に、吸入ステロイド剤（ICS）、β2アゴニスト、ロイコトリエン受容体拮抗薬（LTRAs）、および生物学的製剤が含まれます。吸入ステロイド剤は気道の炎症を抑えるために使用され、喘息発作を防ぐためには重要な役割を果たします。β2アゴニストは気道を広げる効果があり、急性の喘息発作時には短時間作用型（SABA）が使用されます。一方で、長時間作用型（LABA）は日常的な管理に利用されます。

COPDの治療に関しては、主に気道を拡張させる作用のある抗コリン薬とβ2アゴニストが重要です。抗コリン薬には短時間作用型（SAMA）と長時間作用型（LAMA）があり、慢性的な呼吸困難を軽減するために使われます。特に、LAMAは一回の投与で長時間持続するため、COPD患者にとっての治療選択肢として価値があります。

最近では、喘息とCOPDの両方に対する新しい治療法や薬剤が開発されており、生物学的製剤が注目を浴びています。これらの薬剤は、特定の免疫応答に関連する分子を標的として作用し、高い効果を示すことがあります。特に重症喘息に対しては、IL-5やIL-4/IL-13に対する抗体を用いた治療が有望視されています。

治療の選択は患者の症状や生活スタイルに応じて行われ、それぞれの薬剤には副作用があるため、医師の指導のもとで適切な使用が求められます。また、吸入薬の使用には技術が必要であり、患者が正しい使い方を理解することが重要です。吸入デバイスの種類によって、使い方が異なるため、正しい使用法を患者に教育することも医療提供者の重要な役割です。

加えて、喘息やCOPDの患者には、生活習慣の改善や環境因子の管理も重要です。禁煙や運動、栄養管理などは、薬物治療と合わせて症状の改善に寄与します。さらに、最新の研究では、スマートデバイスやアプリケーションを利用した自己管理の方法が増えてきており、患者に対して自己管理能力を高める手助けが行われています。

喘息とCOPDの治療は多岐にわたりますが、薬物療法、生活習慣の改善、教育など、患者が総合的に管理できるようなアプローチが求められています。今後の研究や技術の進展により、より効果的で個別化された治療が期待されています。そして、喘息やCOPDに関する理解を深め、患者の生活の質を向上させるための取り組みは、医療コミュニティ全体で引き続き継続される必要があると言えます。これらの疾患に対する治療と管理は常に進化しており、患者のニーズに応じた最適な治療法が提供されることが重要です。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 喘息＆COPD治療薬の世界市場見通し2023年-2029年(Drugs for Asthma and COPD Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

喘息＆COPD治療薬の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp